BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38101600)

  • 1. Amino acid derivative of probenecid potentiates apoptosis-inducing effects of vinblastine by increasing oxidative stress in a cancer cell-specific manner.
    Huttunen J; Tampio J; Järvinen J; Montaser AB; Markowicz-Piasecka M; Huttunen KM
    Chem Biol Interact; 2024 Jan; 388():110833. PubMed ID: 38101600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents.
    Huttunen J; Gynther M; Huttunen KM
    Int J Pharm; 2018 Oct; 550(1-2):278-289. PubMed ID: 30149128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cells.
    Montaser A; Markowicz-Piasecka M; Sikora J; Jalkanen A; Huttunen KM
    Int J Pharm; 2020 Aug; 586():119585. PubMed ID: 32599132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP).
    Markowicz-Piasecka M; Huttunen J; Montaser A; Adla SK; Auriola S; Lehtonen M; Huttunen KM
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
    Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
    Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
    Schneiderman RS; Shmueli E; Kirson ED; Palti Y
    BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells.
    Abdelfatah S; Böckers M; Asensio M; Kadioglu O; Klinger A; Fleischer E; Efferth T
    Phytomedicine; 2021 Jun; 86():153196. PubMed ID: 32229058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
    Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.
    Chen Y; Scully M; Petralia G; Kakkar A
    Cancer Biol Ther; 2014 Jan; 15(1):135-45. PubMed ID: 24253450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
    Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
    Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics.
    Goler-Baron V; Assaraf YG
    PLoS One; 2012; 7(4):e35487. PubMed ID: 22530032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.
    Jendželovský R; Jendželovská Z; Kuchárová B; Fedoročko P
    Biomed Pharmacother; 2019 Jan; 109():2173-2181. PubMed ID: 30551474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells.
    Chen YJ; Kuo CD; Chen SH; Chen WJ; Huang WC; Chao KS; Liao HF
    PLoS One; 2012; 7(5):e37006. PubMed ID: 22615870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells.
    Long QZ; Zhou M; Liu XG; Du YF; Fan JH; Li X; He DL
    Anticancer Drugs; 2013 Sep; 24(8):810-7. PubMed ID: 23744557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
    Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
    Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.